Literature DB >> 16157199

Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9).

Constantina Sambani1, Roberta La Starza, Valentina Pierini, Peter Vandenberghe, Juan J Gonzales-Aguilera, Helen Rigana, Daphne Koumbi, Kalliopi N Manola, Chryssa Stavropoulou, Vasileios N Georgakakos, Maria Pagoni, Iwona Wlodarska, Cristina Mecucci.   

Abstract

The unbalanced t(1;9) is a rare, recurrent rearrangement in polycythemia vera (PV) resulting in trisomy of both 1q and 9p arms, whereas a balanced t(1;9)(q12;q12), to our knowledge, has never been reported before. We studied two patients with PV and one with idiopathic myelofibrosis bearing an unbalanced t(1;9) and one patient with essential thrombocythemia with a balanced t(1;9). In all cases fluorescence in situ hybridization showed that the breakpoints were located within the satellite II family of heterochromatin of chromosome 1 and the satellite III of chromosome 9. Heterochromatin breakage and reunion produce the unbalanced t(1;9) and may contribute to a gene dosage effect due to gains of 1q and 9p. Case 4 with the balanced t(1;9), however, suggests that translocation of heterochromatin close to critical genes could interfere with their function. The molecular event underlying juxtaposition of satellite II of chromosome 1 and the satellite III of chromosome 9 remains to be elucidated.

Entities:  

Mesh:

Year:  2005        PMID: 16157199     DOI: 10.1016/j.cancergencyto.2005.02.021

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

1.  A Rare Presentation of Extramedullary Hematopoiesis in Post-polycythemic Myelofibrosis.

Authors:  Ceyla Konca Degertekin; Zübeyde Nur Ozkurt; Nalan Akyürek; Münci Yağcı
Journal:  Indian J Hematol Blood Transfus       Date:  2012-12-07       Impact factor: 0.900

2.  Polyploidy in myelofibrosis: analysis by cytogenetic and SNP array indicates association with advancing disease.

Authors:  Nisha R Singh; Christine M Morris; Mary Koleth; Kelly Wong; Christopher M Ward; William S Stevenson
Journal:  Mol Cytogenet       Date:  2013-12-17       Impact factor: 2.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.